Total trials
2,078
Active
206
Phase 3
567
Total enrollment
947,727
Pipeline matrix
Showing 40 of 223 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ocrelizumab | — | 25 | |||||
| Risdiplam | — | — | 13 | ||||
| Emicizumab | — | — | — | 12 | |||
| Faricimab | — | — | 17 | ||||
| Vevye® | — | — | — | — | — | 1 | |
| Xiidra® | — | — | — | — | — | 1 | |
| Atezolizumab | — | 138 | |||||
| Tocilizumab | — | 110 | |||||
| Inavolisib | — | — | 17 | ||||
| Obinutuzumab | — | 58 | |||||
| Afimkibart | — | — | — | 12 | |||
| Glofitamab | — | — | 16 | ||||
| Bevacizumab | — | 95 | |||||
| Tiragolumab | — | — | — | 31 | |||
| Pemetrexed | — | — | — | — | 23 | ||
| Giredestrant | — | — | — | — | 10 | ||
| Carboplatin | — | 54 | |||||
| Divarasib | — | — | — | 8 | |||
| Rituximab | — | 79 | |||||
| Alectinib | — | — | 22 | ||||
| Methylprednisolone | — | — | — | 17 | |||
| Pembrolizumab | — | — | — | 11 | |||
| Gemcitabine | — | 48 | |||||
| Entrectinib | — | — | 12 | ||||
| Fulvestrant | — | — | 11 | ||||
| Palbociclib | — | — | 9 | ||||
| Cisplatin | — | — | — | 41 | |||
| Satralizumab | — | — | — | — | 10 | ||
| Crovalimab | — | — | — | 10 | |||
| Mosunetuzumab | — | — | — | 9 | |||
| Ipatasertib | — | — | — | 17 | |||
| Fenebrutinib | — | — | — | 6 | |||
| Letrozole | — | — | — | — | 6 | ||
| Enicepatide | — | — | — | 5 | |||
| LHRH Agonist | — | — | — | — | 5 | ||
| Ribociclib | — | — | — | — | 5 | ||
| Paclitaxel | — | 62 | |||||
| Trastuzumab | — | 54 | |||||
| Capecitabine | — | 52 | |||||
| Oxaliplatin | — | 42 |
183 more active programs hidden
Next readouts
- 2019-11-27
- 2021-12-31
- 2022-02-10
- 2022-02-18
- 2022-11-16
- 2023-02-20
- 2023-03-29
- 2023-05-08
- 2023-05-22
- 2023-06-26
Top conditions
- Rheumatoid Arthritis184
- Breast Cancer134
- Healthy Volunteer114
- Anemia89
- Hepatitis C, Chronic79
- Colorectal Cancer70
- HIV Infections61
- Diabetes Mellitus Type 250
Frequently asked questions about Hoffmann-La Roche
- How many clinical trials does Hoffmann-La Roche have on ClinicalTrials.gov?
- Hoffmann-La Roche is listed as the lead sponsor on 2,078 clinical trials in ClinicalTrials.gov, 206 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hoffmann-La Roche's trials are in Phase 3?
- 567 of Hoffmann-La Roche's trials are in Phase 3, spread across 223 active drug programs.
- What therapeutic areas does Hoffmann-La Roche focus on?
- Hoffmann-La Roche's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Breast Cancer, Healthy Volunteer, Anemia, Hepatitis C, Chronic.
- When are Hoffmann-La Roche's next clinical trial readouts?
- Hoffmann-La Roche has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease”, expected around 2019-11-27.